Sorbent Therapeutics Gains $36M
Sunnyvale-based Sorbent Therapeutics, a biopharmaceuticals firm targeting the cardiovascular and renal disease area, has raised $36M in a Series B financing round. The firm said the funding was led by Novartis Venture Funds, and includes existing investors Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem. The firm said the new round ups the company's Series B to a total of $53M.
posted on Thursday, June 30, 2011 (Link to more information)
Related companies:
Sorbent Technologies
Related stories:
> Protagonist Therapeutics Gains $40M
> Nuon Therapeutics Gains $5M
> Pearl Therapeutics Gains $65M
> Merck Buys Sirna Therapeutics
> Iconic Therapeutics Finds $20M
silicontap.com Home